跳至主要内容
临床试验/NL-OMON49417
NL-OMON49417招募中不适用

Intra-operative visualization and treatment of salivary glands affected by sjögren*s syndrome using contrast enhanced ultrasound sialendoscopy (ceuss): a pilot study - Sialendoscopy and ultrasound

Vrije Universiteit Medisch Centrum0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - A diagnosed (by the 2002 ACR-EULAR criteria) primary or secondary Sjögren*s
  • - Age: *18 years and * 80 years
  • - A remaining salivary flow: UWS*0.02, SWS*0.10 ml/min

排除标准

  • - A remaining salivary flow: UWS<0.02, SWS<0.10 ml/min
  • - When it is not possible to identify and enter the orifice of the salivary
  • duct(s) (determined during T-6)
  • - Acute sialadenitis, severe illness or physical conditions interfering with
  • the intervention
  • - Use of sialogogue medication (i.e. Pilocarpine)
  • - A history of head and neck radiotherapy
  • - Cardiac patients with an (suspected) acute coronary syndrome, recent
  • percutaneous coronary intervention, acute or chronic severe [New York Heart
  • Association (NYHA) class III/IV] heart failure, right-to-left shunts, severe
  • pulmonary hypertension (pulmonary artery pressure >90*mmHg) or uncontrolled
  • hypertension, adult respiratory distress syndrome or severe cardiac
  • dysrhythmias.
  • - Use of Dobutamine. Sonovue should not be used in combination with dobutamine
  • (used for heart failure) in patients with conditions that suggest
  • cardiovascular instability where dobutamine is contraindicated.
  • - Presence of MALT-lymphoma in the major salivary glands

研究者

相似试验